Please login to the form below

Not currently logged in
Email:
Password:

Shire divests non-core products for USD 213m

Shire agrees to sell a portfolio of non-core products to Spanish-headquartered Almirall Prodesfarma for USD 213m in cash

UK-based pharmaceutical company Shire Pharmaceuticals has agreed to sell a portfolio of non-core products to Spanish-headquartered Almirall Prodesfarma for USD 213m in cash.

The transaction is subject to competition clearances and other customary consents. Shire was advised by Rothschild.

Almirall will gain sunlight skin lesion treatment Solaraze, as well as Vaniqa, a cream used on female facial hair. Six non-promoted products, which are sold in the UK, France, Germany, Italy, Spain and Ireland, are also bundled in with the deal.

The six other products include Lodine (etodolac) for treatment of rheumatoid arthritis and osteoarthritis, Colazide (balsalazide) for treatment of mild to active ulcerative colitis, Meptid (meptazinol) for treatment of pain, and Cebutid (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis.

Shire said the core focus of the firm was to build its attention deficit hyperactivity disorder (ADHD), human genetic therapies, gastrointestinal and renal diseases businesses.

Shire will expand its ADHD expertise to markets outside the US within the next two years, with an initial focus on the EU.

The company concluded that with its recent in-licensing of Juvista, an experimental treatment for scarring, from UK-based Renovo, it will build a new specialty area of regenerative medicine.

Shire's CEO, Matthew Emmens, said: "Our strategic focus is clear and our emphasis in the international markets is on developing competitive positions for our global products that meet the needs of the specialist physicians and their patients, in our chosen areas of expertise."

Almirall's CEO, Dr Jorge Gallardo, added: "We are very satisfied with this acquisition since it expands our international presence in a critical market like the UK and reinforces our position as one of the key European specialty pharmaceutical companies".

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics